Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg
- PMID: 36750165
- DOI: 10.1016/j.jinf.2023.02.002
Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg
Conflict of interest statement
Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Comment in
-
Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.J Infect. 2023 Sep;87(3):282-285. doi: 10.1016/j.jinf.2023.06.024. Epub 2023 Jul 13. J Infect. 2023. PMID: 37451364 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources